

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10582704	
	Filing Date		2004-12-14	
	First Named Inventor	Maria Isabel Crespo Crespo		
	Art Unit	1624		
	Examiner Name			
Attorney Docket Number		690068.601USPC		

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	EP 1 283 056	EP	B1	2004-12-15	Yasuda et al.		<input type="checkbox"/>
	2	EP 1 439 175	EP	A1	2004-07-21	Harada et al.		<input type="checkbox"/>
	3	WO 01/62233	WO	A2	2001-08-30	Borroni et al.		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10582704
Filing Date		2004-12-14
First Named Inventor	Maria Isabel Crespo Crespo	
Art Unit	1624	
Examiner Name		
Attorney Docket Number	690068.601USPC	

4	WO 02/47690	WO	A1	2002-06-20	Cai et al.		<input type="checkbox"/>
5	WO 03/035639	WO	A1	2003-05-01	Harada et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T's
	1	AUCHAMPACH and BOLLI, "Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges," Am. J. Physiol. 276(3 pt 2): H1113-6, 1999	<input type="checkbox"/>
	2	COSTELLO-BOERRIGTER et al., "Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics," Med. Clin. North Am. 87(2): 475-491, March 2003	<input type="checkbox"/>
	3	DUNWIDDIE and MASINO, "The Role and Regulation of Adenosine in the Central Nervous System," Annu. Rev. Neurosci. 24: 31-55, 2001	<input type="checkbox"/>
	4	FEOKTISTOV and BIAGGIONI, "Adenosine A2B Receptors," Pharmacol. Rev. 49(4): 381-402, 1997	<input type="checkbox"/>
	5	GOTTLIEB, "Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure," Drugs 61(10): 1387-93, 2001	<input type="checkbox"/>
	6	HAPPE et al., "Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome," Neuropsychobiology 48: 82-86, 2003	<input type="checkbox"/>
	7	HESS, "Recent advances in adenosine receptor antagonist research," Expert Opin. Ther. Patents 11(10): 1533-61, 2001	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10582704
Filing Date	2004-12-14
First Named Inventor	Maria Isabel Crespo Crespo
Art Unit	1624
Examiner Name	
Attorney Docket Number	690068.601USPC

8	JENNER, "Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments," J. Neurol. 247 (Suppl 2): II/43-II/50, 2000	<input type="checkbox"/>
9	NORTON et al., "Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart," Am. J. Physiol. 275(2 pt 2): H341-9, 1999	<input type="checkbox"/>
10	POPOLI et al., "Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum," J. Neurosci. 22(5): 1967-75, March 1, 2002	<input type="checkbox"/>
11	STONE et al., "Neuroprotection by A2A Receptor Antagonists," Drug Development Research 52: 323-330, 2001	<input type="checkbox"/>
12	TUITE and RISS, "Recent developments in the pharmacological treatment of Parkinson's disease," Expert Opin. Investig. Drugs 12(8): 1335-52, 2003	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Deepak Rao/	Date Considered	03/02/2010
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/